安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- People With Severe Diabetes Are Cured in Small Trial of New . . .
A person’s conventional supplies for treating type 1 diabetes A single infusion of a new treatment, called zimislecel, may have cured 10 out of 12 people with the most severe form of the disease
- Zimislecel, a novel cell therapy, appears to restore islet . . .
Results from the phase 1 2 portion of the FORWARD-101 trial, which enrolled patients with type 1 diabetes with severe hypoglycemic events and impaired hypoglycemic awareness, were presented at the
- Small trial in US of new treatment cures people with severe . . .
Small trial in US of new treatment cures people with severe diabetes 2025-06-22 - Gina Kolata A single infusion of a stem cellbased treatment may have cured 10 out of 12 people with the most severe form of Type 1 diabetes A year later, these 10 patients no longer need insulin The other two patients need much lower doses
- Vertex Presents Positive Data for Zimislecel in Type 1 . . .
BOSTON, June 20, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1 2 portion of the Phase 1 2 3
- Son’s diabetes diagnosis sent scientist on quest for cure
In 2019, the company was acquired by Vertex, and it now conducts clinical trials for people with Type 1 Melton said more than a dozen patients have completed the trial and “more than a handful” who have taken this new treatment are “insulin independent” — meaning they have not required additional exogenous insulin thus far
- Diabetes Breakthrough: New Treatment Eliminates Insulin for . . .
A new treatment combining ReCET and semaglutide could eliminate the need for insulin in type 2 diabetes, with 86% of participants in a study no longer requiring insulin therapy The treatment was safe and well-tolerated, and further trials are planned to confirm these results
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk . . .
In this randomized, placebo-controlled trial involving persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, daily oral semaglutide was
|
|
|